Amondys 45™ (casimersen) – New orphan drug approval
February 25, 2021 - The FDA announced the approval of Sarepta’s Amondys 45 (casimersen), for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping.
Download PDF
